As of November 6, 2026, Crescent Biopharma, Inc. is a publicly traded company (Nasdaq: CBIO). The largest holder reporting an active stake on Schedule 13D is Fairmount Funds Management LLC, at 16.52%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Fidelity (FMR) (15%), 1Globe Capital LLC (10.3%), Venrock Healthcare Capital Partners III, L.P. (9.5%) (Schedule 13D/A, July 20, 2026).
Is this your company?
About to sign with, pay or invest in Crescent Biopharma, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Crescent Biopharma, Inc. a real, registered company?
- Crescent Biopharma Inc files with the SEC under CIK 1253689 (its SEC filings).
- Its shares are listed under the ticker CBIO on Nasdaq (SEC company record).
- Incorporated in E9; business address in Waltham, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under CRESCENT BIOPHARMA INC in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-27).
Who are Crescent Biopharma, Inc.'s owners and officers?
Crescent Biopharma, Inc.: business address in Waltham, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G, 2026-10-27).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-27 | Blackrock, Inc. | 5.6% |
| Schedule 13G/A, 2026-08-14 | Balyasny Asset Management L.P. | 6.03% |
| Schedule 13D/A, 2026-07-20 | Fairmount Funds Management LLC | 16.52% |
| Schedule 13G/A, 2026-05-15 | Tang Capital Management, LLC | 4.21% |
| Schedule 13G, 2026-05-15 | Balyasny Asset Management L.P. | 5.48% |
| Schedule 13G, 2026-02-17 | Vestal Point Capital, LP | 5.4% |
| Schedule 13G/A, 2026-02-17 | Venrock Healthcare Capital Partners Iii, L.P. | 9.5% |
| Schedule 13G/A, 2026-02-05 | Fmr LLC | 15% |
| Schedule 13G, 2025-12-11 | Forgrowth Iii Pa B.V. | 6.1% |
| Schedule 13D/A, 2025-12-08 | Fairmount Funds Management LLC | 18.53% |
| Schedule 13G/A, 2025-10-14 | 1globe Capital LLC | 10.3% |
| Schedule 13G, 2025-10-09 | Tang Capital Management, LLC | 5.04% |
Questions about who owns Crescent Biopharma, Inc.
Who owns Crescent Biopharma, Inc.?
On this page, 8 holders' latest ownership filings report 5% or more of Crescent Biopharma, Inc.: Fairmount Funds Management LLC (16.52%, Schedule 13D/A, filed 2026-07-20), Fmr LLC (15%, Schedule 13G/A, filed 2026-02-05), 1globe Capital LLC (10.3%, Schedule 13G/A, filed 2025-10-14), Venrock Healthcare Capital Partners Iii, L.P. (9.5%, Schedule 13G/A, filed 2026-02-17) and Forgrowth Iii Pa B.V. (6.1%, Schedule 13G, filed 2025-12-11); 3 more are listed above.
Who are the largest shareholders of Crescent Biopharma, Inc.?
By the share each holder's latest filing reports, the largest holders of Crescent Biopharma, Inc. on this page are Fairmount Funds Management LLC (16.52%), Fmr LLC (15%) and 1globe Capital LLC (10.3%).
When did Fairmount Funds Management LLC buy into Crescent Biopharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fairmount Funds Management LLC on this page is the Schedule 13D/A, filed 2025-12-08, reporting 18.53%; its latest, Schedule 13D/A filed 2026-07-20, reports 16.52%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Crescent Biopharma, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Crescent Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Crescent Biopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Crescent Biopharma, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director and 10% owner: 3,601,316 shares (9.7% of shares outstanding), held indirectly through By Fairmount Healthcare Fund II L.P., on a joint filing (Form 4, 2026-07-20).
- Fairmount Healthcare Fund II L.P., a director and 10% owner: 3,601,316 shares (9.7% of shares outstanding), held indirectly through By Fairmount Healthcare Fund II L.P., on a joint filing (Form 4, 2026-07-20).
- , a director and 10% owner: 3,601,316 shares (9.7% of shares outstanding), held indirectly through By Fairmount Healthcare Fund II L.P., on a joint filing (Form 4, 2026-07-20).
- Fairmount Funds Management LLC, a director and 10% owner: 3,601,316 shares (9.7% of shares outstanding), held indirectly through By Fairmount Healthcare Fund II L.P., on a joint filing (Form 4, 2026-07-20).
- , the chief executive and a director: 271,765 shares (0.73% of shares outstanding) (Form 4, 2026-09-18).
Shares outstanding: 37,143,940 as of 2026-07-27, from the company's latest SEC cover page.
How much has Crescent Biopharma, Inc. raised?
Latest IPO step: Crescent Biopharma, Inc. filed to go public (S-1, 2026-01-07).
IPO filings: S-1, 2026-01-07.
Keep reading
More on Crescent Biopharma, Inc. and the records around it.
Crescent Biopharma, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- 1Globe Capital LLC also filed stake reports on 1 other company: SINOVAC BIOTECH LTD (Sep 2025)
- ForGrowth III PA B.V. also filed stake reports on 4 other companies: Aura Biosciences, Inc. (Oct 2026), Vor Biopharma Inc. (Dec 2025), Astria Therapeutics, Inc. (Nov 2025)
- Fairmount Funds Management LLC also filed stake reports on 13 other companies: Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/crescent-biopharma